new drug under development

Description Results NMA

Intravenous Levosimendan (n=299)

vs.

placebo (n=301)

double blind

Parallel groups

Sample size: 299/301

Primary endpoint: worsening heart failure

FU duration: 5 days

levosimendan 0.1–0.2 mg/kg/min (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint: composite clinical

FU duration:

Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: hypotension or myocardial ischaemia

FU duration: 14 days

all cause death (6M+) 0.91 [0.74; 1.12]

Short term death (30d) 0.85 [0.63; 1.15]

Intravenous levosimendan (n=664)

vs.

intravenous dobutamine (n=663)

double-blind

Parallel groups

Sample size: 664/663

Primary endpoint: all cause mortality

FU duration: 180 days

Levosimendan 16 mg/kg þ 0.2 mg/kg/min (n=-9)

vs.

Dobutamine (10 mg/kg/min) and placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

Levosimendan (n=-9)

vs.

Dobutamine (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: haemodynamic improvement

FU duration: 24h

all cause death 1.48 [0.31; 7.03]

all cause death 4.88 [0.58; 41.10]

amelioration of Dyspnea at 24 h 1.11 [1.03; 1.19]

all cause death 0.90 [0.71; 1.14]

30-d HF rehospitalization 0.98 [0.82; 1.19]

30-d death or HF hospitalization 0.93 [0.81; 1.08]

30 day death 0.90 [0.71; 1.14]

nesiritide(0.015 and 0.030 microg/kg/min (n=85)

vs.

placebo (n=42)

Sample size: 85/42

Primary endpoint:

FU duration:

nesiritidefor at least 12h (n=127)

vs.

placebo (n=123)

double-blind

Parallel groups

Sample size: 127/123

Primary endpoint:

FU duration: 30 days

nesiritide as a 0.01-µg/kg/min infusion for 48 hours (n=39)

vs.

placebo (n=36)

Double blind

Parallel groups

Sample size: 39/36

Primary endpoint: >20% increase in SCr anytime during 1st hospital week

FU duration: 7 days

nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours) (n=911)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 911/0

Primary endpoint: mortality and CV or renal hospitalization

FU duration: 12 weeks

intravenous nesiritide for 24 hours to 7 days on top of standard therapy (n=3496)

vs.

matching placebo (n=3511)

double-blind

Parallel groups

Sample size: 3496/3511

Primary endpoint: coprimary: dyspnea, death or HF hospitalization

FU duration: 30 days

intravenous nesiritidefor 3 hours (n=204)

vs.

placebo (n=142)

3rd arms with IV nitroglycerin for 3 hours(n=143)

double-blind

Sample size: 204/142

Primary endpoint:

FU duration:

nesiritide(0.015 and 0.030 microg/kg/min (n=203)

vs.

usual care (n=102)

open

Parallel groups

Sample size: 203/102

Primary endpoint:

FU duration: <5 days

all cause death 1.56 [0.80; 3.04]

nesiritideinfusion for 24 hours (n=280)

vs.

nitroglycerin (n=218)

Sample size: 280/218

Primary endpoint:

FU duration:

nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly (n=-9)

vs.

standard care (n=-9)

open

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

nesiritide(0.015 or 0.03 microg/kg/min) (n=-9)

vs.

Dobutamine (> or =5 microg/kg/min) (n=-9)

open

Parallel groups

Sample size: -9/-9

Primary endpoint: ECG Holter

FU duration:

treatment success 0.92 [0.78; 1.09]

daily intravenous rolofylline (30 mg) for up to 3 days (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: treatment success

FU duration: 3 days (60 days)

48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation (n=-9)

vs.

placebo (on top stnadard care) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily (n=172)

vs.

placebo (n=62)

double blind

Parallel groups

Sample size: 172/62

Primary endpoint: none defined

FU duration:

dose-finding phase IIb study